J Am Pharm Assoc (2003). 2021 Mar-Apr;61(2):e75-e79. doi: 10.1016/j.japh.2020.09.020. Epub 2020 Oct 14.
Groundbreaking new laws granting community pharmacists the authority to prescribe human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) medications have the potential to substantially expand PrEP access in high-risk communities. However, whether patients will be accepting of pharmacists as PrEP providers is underexplored within the literature.
To assess patient perspectives of pharmacist PrEP prescribing and identify potential barriers to acceptance of pharmacist-prescribed PrEP.
Adult patients currently receiving antiretroviral therapy for HIV prophylaxis or treatment at a specialty pharmacy were surveyed telephonically from January 2020-April 2020. A 4-point Likert scale was used to measure perceptions in addition to open-ended questions.
The participation rate was 87.5%. Of the 49 included patients, 100% agreed/strongly agreed that pharmacists were knowledgeable about medications, but they were less likely to strongly agree that pharmacists were knowledgeable about HIV drugs (14.3% vs. 75.5% for other drugs, P < 0.001). Most (93.9%) of the patients agreed/strongly agreed that they would feel comfortable seeking a pharmacist for PrEP information or HIV testing. With respect to PrEP prescribing, 16.3% disagreed that they would feel comfortable having a pharmacist prescribe their first fill of PrEP, preferring to speak to their physician or expressing concerns that pharmacists have inadequate training. All patients expressed a desire for additional HIV/PrEP training requirements for pharmacists before allowing them to prescribe PrEP. A portion of the respondents (18.4%) expressed concerns that the increased availability of PrEP would lead to persons becoming lax about barrier protection. However, 100% of the patients agreed/strongly agreed that having pharmacist-prescribed PrEP would benefit their community.
Patients receiving antiretroviral therapy reported overall favorable perceptions of pharmacist PrEP prescribing; however, some concerns relating to pharmacists' level of training in HIV exist. This may be ameliorated through increased pharmacist education, including how to counsel patients seeking PrEP on behavioral risk reduction.
赋予社区药剂师开具人类免疫缺陷病毒 (HIV) 暴露前预防 (PrEP) 药物处方权的开创性新法律有可能大大扩大高危社区的 PrEP 可及性。然而，文献中对患者是否接受药剂师作为 PrEP 提供者的看法探讨甚少。
评估患者对药剂师开具 PrEP 处方的看法，并确定接受药剂师开具 PrEP 的潜在障碍。
2020 年 1 月至 2020 年 4 月，通过电话对在一家专业药房接受抗逆转录病毒治疗预防或治疗 HIV 的成年患者进行了调查。使用 4 分制量表来衡量患者的看法，此外还提出了开放式问题。
参与率为 87.5%。在 49 名入组患者中，100%的患者同意/强烈同意药剂师对药物有足够的了解，但他们不太可能强烈同意药剂师对 HIV 药物有足够的了解（对其他药物的同意率为 75.5%，对 HIV 药物的同意率为 14.3%，P < 0.001）。大多数（93.9%）患者同意/强烈同意他们会感到舒适地向药剂师寻求 PrEP 信息或 HIV 检测。关于 PrEP 处方，16.3%的患者不同意他们会感到舒适地让药剂师开他们的第一剂 PrEP 处方，他们更愿意与医生交谈或表达对药剂师培训不足的担忧。所有患者都表示希望在允许药剂师开 PrEP 处方之前，对药剂师进行更多的 HIV/PrEP 培训要求。一部分受访者（18.4%）表示担心 PrEP 的可及性增加会导致人们对屏障保护变得松懈。然而，100%的患者同意/强烈同意让药剂师开 PrEP 处方会使他们的社区受益。
接受抗逆转录病毒治疗的患者总体上对药剂师开具 PrEP 处方的看法较为积极；然而，他们对药剂师在 HIV 方面的培训水平存在一些担忧。通过增加药剂师教育，包括如何就行为风险降低向寻求 PrEP 的患者提供咨询，这种情况可能会得到改善。
